Seth Gordon, MBA

Perspectives

Approaching Clinical Pathway Development as an Art

11/18/2020

Richard G Stefanacci, DO, MGH, MBA, AGSF, CMD

Craig Ornstein, PhD

Seth Gordon, MBA

Abstract: In health care, rules and regulations are in place for good reason, but there is an art to integrating them into care effectively to benefit patients as well as the other stakeholders—clinically and...

...

11/18/2020

Journal of Clinical Pathways

Clinical Pathways GPS

Clinical Pathways and Policy to Guard Against Misaligned Incentives

02/18/2020

Mathew Pakizegee, PharmD, MS

Richard G Stefanacci, DO, MGH, MBA, AGSF, CMD—Column Editor

Seth Gordon, MBA

The application of clinical pathways and their enforcement through quality metric benchmark setting and appropriate use criteria is needed to guard against perverse financial incentives that encourage overutilization...

The...

02/18/2020

Journal of Clinical Pathways

Clinical Pathways GPS

Impact of Quality of Life on Clinical Pathways

08/02/2016

Jill Cantelmo, DPhil, MSc

Seth Gordon, MBA

Richard G Stefanacci, DO, MGH, MBA, AGSF, CMD—Column Editor

For clinical pathway developers seeking to define the value of different treatments, quality-of-life (QOL) measures offer a means of capturing the factors that most define value to the patient and their caregivers....

For...

08/02/2016

Journal of Clinical Pathways

Clinical Pathways GPS

Hitting Each Component of the Triple Aim Along the Clinical Pathway

05/06/2016

Richard G Stefanacci, DO, MGH, MBA, AGSF, CMD—Column Editor

Scott Guerin, PhD

Seth Gordon, MBA

The concept of the Triple Aim—improving the experience of care, reducing the costs of care, and improving the health of populations—is increasingly becoming important to drug manufacturers, who must demonstrate how...

The...

05/06/2016

Journal of Clinical Pathways